

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**FingerTango Inc.**

指尖悅動控股有限公司

*(incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 6860)**

**APPOINTMENT OF EXECUTIVE DIRECTOR;  
CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS;  
CHANGE IN COMPOSITION OF BOARD COMMITTEES; AND  
CHANGE OF AUTHORISED REPRESENTATIVE**

**APPOINTMENT OF EXECUTIVE DIRECTOR**

The board (the “**Board**”) of directors (the “**Directors**” each a “**Director**”) of FingerTango Inc. (the “**Company**”, and together with its subsidiaries, the “**Group**”) is pleased to announce that, Dr. Chan Man Fung (“**Dr. Chan**”) has been appointed as an executive Director and a member of the remuneration committee of the Company (the “**Remuneration Committee**”) with effect from 29 June 2023.

The biographical details of Dr. Chan are set out below:

Dr. Chan, aged 36, received his Postgraduate Diploma in Business Administration from the Society of Business Practitioners of Cheshire, England in 2017, obtained his doctorate degree in Business Administration from Warnborough College, Ireland in 2016 and received his Postgraduate Diploma in Legal Practice from the University of Oxford, England in 2011. He was graduated from the University of London with a bachelor degree of Laws in 2007 and from The Hong Kong Polytechnic University with a bachelor degree of Arts with a major in Business Studies in 2006. Dr. Chan also is a fellow member of Society of Business Practitioners of Cheshire, England and a practicing chartered legal executive lawyer in England. Dr. Chan was a licensed person for types 1 (dealing in securities), 2 (dealing in future contracts), 4 (advising on securities) and 9 (asset management) regulated activities under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) (the “**SFO**”) and currently is the substantial shareholder of a corporation licensed by the Securities and Futures Commission (the “**SFC**”) to carry out types 1 (dealing in securities), 4 (advising on securities) and 9 (asset management) regulated activities under the SFO. Dr. Chan is a merchant having businesses and investments in Hong Kong and the People’s

Republic of China (the “**PRC**”). Dr. Chan has extensive experience in corporate finance and the legal and financial services fields both in the PRC and Hong Kong and was involved in several merger and acquisition transactions and initial public offerings. Dr. Chan is currently an executive director and co-chairman of P.B. Group Limited (Stock Code: 8331), a company listed on the GEM of The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”).

Dr. Chan has entered into a service agreement with the Company commencing on 29 June 2023 for a term of three years, subject to retirement by rotation and re-election at the annual general meeting of the Company in accordance with the articles of association of the Company (the “**Articles of Association**”). Under the service agreement, Dr. Chan will be entitled to a remuneration of HK\$240,000 per annum which was determined by the Board with reference to his experience, duties and responsibilities as well as prevailing market rates. Pursuant to the Articles of Association, Dr. Chan shall hold office until the next annual general meeting of the Company where he shall be eligible for re-election.

Save as disclosed above, Dr. Chan confirmed that, as at the date of this announcement, he has not held any directorship, and/or any other major appointment and professional qualification in other companies listed on the Stock Exchange and/or overseas in the last three years. He has no relationships with any Directors, senior management or substantial or controlling shareholders of the Company, has no other major positions in the Group, and does not have any interest in any shares, underlying shares or debentures of the Company or any of its associated corporation which are required to be disclosed pursuant to Part XV of the SFO.

Save as disclosed herein, the Board is not aware of any other information relating to the appointment of Dr. Chan that need to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Rules (the “**Listing Rules**”) Governing the Listing of Securities on the Stock Exchange.

The Board would like to take this opportunity to welcome Dr. Chan for joining the Board.

## **CHANGE OF INDEPENDENT NON-EXECUTIVE DIRECTORS**

### **Resignation of independent non-executive Director**

The Board hereby announces that, Mr. Sui Pengda (“**Mr. Sui**”) has tendered his resignation as an independent non-executive Director and a member of each of the audit committee of the Company (the “**Audit Committee**”), Remuneration Committee and nomination committee of the Company (the “**Nomination Committee**”) with effect from 29 June 2023 due to his other business engagement.

Mr. Sui has confirmed that he has no disagreement with the Board and there are no matters relating to his resignation that need to be brought to the attention to the shareholders of the Company and the Stock Exchange.

The Board would like to express its sincere gratitude to Mr. Sui for his valuable contributions to the Company during his tenure.

### **Appointment of independent non-executive Director**

The Board is pleased to announce that Mr. Jiang Huihui (“**Mr. Jiang**”) has been appointed as an independent non-executive Director and a member of each of the Audit Committee, Remuneration Committee and Nomination Committee with effect from 29 June 2023.

The biographical details of Mr. Jiang are set out below:

Mr. Jiang, aged 39, obtained a bachelor degree of Engineering from University of Central Lancashire in 2005 and a degree of Master of Engineering Studies from University of Technology, Sydney in 2007. Mr. Jiang has extensive experience in finance, investment fund management and the media and entertainment related businesses. Mr. Jiang is currently the general manager of an assets management company located in Beijing, the PRC, responsible for the management of overall operation of the company. Mr. Jiang is also the management consultant of a film and television production company located in Beijing, the PRC, responsible for identifying issues in the company and developing plans of action for enhancing performance.

The Company has entered into a letter of appointment with Mr. Jiang commencing on 29 June 2023 for a term of three years, subject to retirement by rotation and re-election at annual general meetings of the Company in accordance with the Articles of Association. Under the letter of appointment, Mr. Jiang will be entitled to a director’s fee of HK\$200,000 per annum which was determined by the Board with reference to his experience, duties and responsibilities as well as prevailing market rates. Pursuant to the Articles of Association, Mr. Jiang shall hold office until the next annual general meeting of the Company where he shall be eligible for re-election.

Save as disclosed above, as at the date of this announcement, Mr. Jiang confirmed that, he has not held any directorship, and/or any other major appointment and professional qualification in other companies listed on the Stock Exchange and/or overseas in the last three years. He has no relationships with any Directors, senior management or substantial or controlling shareholders of the Company, has no other major positions in the Group, and does not have any interest in any shares, underlying shares or debentures of the Company or any of its associated corporation which are required to be disclosed pursuant to Part XV of the SFO.

As at the date of this announcement, Mr. Jiang confirmed that, he has met the independent criteria set out in Rule 3.13 of the Listing Rules. Save as disclosed herein, the Board is not aware of any other information relating to the appointment of Mr. Jiang that need to be disclosed pursuant to any of the requirements of Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules.

The Board would like to extend its welcome to Mr. Jiang for joining the Board.

## **CHANGE IN COMPOSITION OF BOARD COMMITTEES**

Following the above mentioned resignation and appointment, the composition of the Board committees has changed with effect from 29 June 2023 as follows:

1. Dr. Chan has been appointed as a member of the Remuneration Committee;
2. Mr. Sui has ceased to be a member of each of the Audit Committee, Remuneration Committee and Nomination Committee; and
3. Mr. Jiang has been appointed as a member of each of the Audit Committee, Remuneration Committee and Nomination Committee.

## **CHANGE OF AUTHORISED REPRESENTATIVE**

The Board hereby announces that Mr. Liu Jie (“**Mr. Liu**”) has ceased to be an authorised representative of the Company (the “**Authorised Representative**”) under Rule 3.05 of the Listing Rules with effect from 29 June 2023. The Board is pleased to announce that Dr. Chan Man Fung has been appointed as the Authorised Representative in replacement of Mr. Liu with effect from 29 June 2023.

By order of the Board  
**FingerTango Inc.**  
**LIU Jie**  
*Chairman and Chief Executive Officer*

Guangzhou, the People’s Republic of China, 29 June 2023

*As at the date of this announcement, the Board comprises Mr. LIU Jie and Dr. CHAN Man Fung as executive Directors and Dr. LIU Jianhua, Mr. GUO Jingdou and Mr. JIANG Huihui as independent non-executive Directors.*